Disclosure of onset-predictive biomarker results to research participants at risk of genetic frontotemporal dementia: a European perspective

Abstract Background As understanding of biomarkers for genetic frontotemporal dementia (FTD) advances, there is a need to develop onset-predictive biomarker tests (OPBTs) to detect changes before the onset of symptoms. OPBTs can be used to recruit carriers or individuals at 50% risk of carriership i...

Description complète

Détails bibliographiques

Auteurs principaux:	Charlotte H. Graafland, Eline M. Bunnik, Barbara Borroni, Arabella Bouzigues, Sergi Borrego-Écija, Eino Solje, Caroline Graff, Jonathan D. Rohrer, John C. van Swieten, Laura Donker Kaat, Harro Seelaar
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-12-01
Collection:	Alzheimer’s Research & Therapy
Sujets:	Clinical trials Disclosure Frontotemporal dementia Ethics Biomarkers
Accès en ligne:	https://doi.org/10.1186/s13195-025-01930-4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!